GlassScriptPhysician profile
Stephanie Strohmeyer
NPI 1447882014
$15,977.63
in general payments reported to CMS, 2019-2025
33 companies · $4,500 in 2025
The $4,500 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,238 · 2022: $2,191 · 2023: $3,259 · 2024: $4,789 · 2025: $4,500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,170.38 |
| Education | $377.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,756.77 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $1,276.31 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Janssen Biotech, INC. | $1,206.95 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Incyte Corporation | $1,198.25 | 2021-2025 | Opzelura, Opzelura |
| Genzyme Corporation | $1,141.68 | 2021-2025 | |
| Galderma Laboratories, L.P. | $967.08 | 2022-2025 | Nemluvio, Aklief, Oracea |
| Ucb, INC. | $728.84 | 2021-2025 | Bimzelx, Cimzia |
| Dermavant Sciences, INC. | $713.57 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $698.86 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $601.63 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $578.78 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $538.49 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $501.70 | 2021-2025 | Jublia, Arazlo, Cabtreo |
| Pfizer INC. | $496.98 | 2021-2025 | |
| Amgen INC. | $483.91 | 2021-2025 | Otezla, Otezla |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $468.07 | 2021-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $432.57 | 2023-2025 | Adbry, Anzupgo |
| Almirall LLC | $389.96 | 2021-2025 | Klisyri, Seysara |
| Organon LLC | $126.45 | 2025 | Vtama |
| Vyne Pharmaceuticals INC. | $82.53 | 2021 | |
| Sebela Pharmaceuticals INC. | $81.00 | 2021-2023 | Naftin |
| Lnhc, INC | $80.11 | 2025 | Zelsuvmi |
| Helsinn Therapeutics (U.S.), INC. | $76.74 | 2022 | |
| Journey Medical Corporation | $69.04 | 2023-2025 | |
| Mayne Pharma Commercial LLC | $66.89 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $49.37 | 2024 | Tremfya |
| Ani Pharmaceuticals, INC. | $40.09 | 2025 | Oxistat |
| Medtronic, INC. | $28.57 | 2024 | Closurefast |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.29 | 2025 | Spevigo |
| Blueprint Medicines Corporation | $24.63 | 2025 | Ayvakit |
| Tempus Ai, INC | $16.29 | 2024 | Merlin Test |
| Paratek Pharmaceuticals, INC. | $14.84 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.39 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Strohmeyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.